Innate Pharma S.A. (IPHA)
NASDAQ: IPHA · Real-Time Price · USD
1.695
-0.005 (-0.29%)
At close: Sep 25, 2026, 4:00 PM EDT
1.700
+0.005 (0.29%)
After-hours: Sep 25, 2026, 4:10 PM EDT

Innate Pharma Financials Overview

Millions EUR. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
9.819.0120.1261.6457.6724.7
Revenue Growth
8.92%-55.25%-67.36%6.88%133.47%-64.59%
Gross Profit
-30.17-34.62-31.865.626.01-22.3
Operating Income
-47.59-54.01-51.58-12.67-16.43-47.83
Net Income
-47.46-49.18-49.47-7.57-58.1-52.81
Earnings Per Share
-0.51-0.55-0.61-0.09-0.73-0.66
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
10.934.3180.7792.46101.49119.84
Total Debt
20.2122.573139.8942.2544.25
Net Cash (Debt)
-9.3111.7449.7852.5659.2375.59
Net Cash Growth
--76.42%-5.30%-11.26%-21.63%-42.98%
Net Cash Per Share
-0.100.130.610.650.740.95

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-42.64-52.76-6.9-32.56-19.16-58.46
Capital Expenditures
-0.17-0.14-0.39-0.35-0.54-0.93
Free Cash Flow
-42.81-52.9-7.29-32.91-19.69-59.39
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
---158.34%9.12%10.42%-90.28%
Operating Margin
-485.25%-599.77%-256.32%-20.55%-28.48%-193.60%
Pretax Margin
-483.85%-546.11%-245.87%-12.28%-100.52%-184.10%
Profit Margin
-483.85%-546.11%-245.87%-12.28%-100.74%-213.78%
FCF Margin
-436.45%-587.40%-36.22%-53.39%-34.14%-240.40%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
13.7416.407.953.434.5814.24